Table 3.
Associations of CYP4F2, APOE and CYP2A6 SNPs with warfarin sensitivity during the stabilization phase of therapy of 139 cardiovascular patients treated with warfarin
| Gene | SNP ID | Genotype | Sensitivea | Moderateb | Resistancec | Overall P-value* |
|---|---|---|---|---|---|---|
| CYP4F2 | rs2108622 | CC | (10/61) 16.4% | (39/61) 63.9% | (12/61) 19.7% | 0.66 |
| P-value* | 0.84 | 0.90 | 0.61 | |||
| CT | (9/59) 15.3% | (35/59) 59.3% | (15/59) 25.4% | |||
| P-value* | 0.97 | 0.87 | 0.92 | |||
| TT | (1/19) 5.3% | (12/19) 63.2% | (6/19) 31.6% | |||
| P-value* | 0.47 | 0.99 | 0.69 | |||
|
APOE |
rs7412 | CC | (17/122) 13.9% | (76/122) 62.3% | (29/122) 23.8% | 0.67 |
| P-value* | 0.68 | 0.84 | 1 | |||
| TC | (3/13) 23.1% | (7/13) 53.8% | (3/19) 23.1% | |||
| P-value* | 0.68 | 0.84 | 1 | |||
| APOE | rs405509 | GG | (8/42) 19% | (29/42) 69% | (5/42) 12% | 0.24 |
| P-value* | 0.1 | 0.52 | 0.59 | |||
| GT | (7/61) 11.5% | (35/61) 57.4% | (19/61) 31.1% | |||
| P-value* | 0.69 | 0.63 | 0.19 | |||
| TT | (5/36) 13.9% | (22/36) 61.1% | (9/36) 25% | |||
| P-value* | 1 | 1 | 0.98 | |||
|
CYP2A6 |
rs1801272 | AA | (18/135) 13.3% | (85/135) 63% | (32/135) 23.7% | 0.10 |
| P-value* | 0.12 | 0.31 | 1 | |||
| TA | (3/4) 50% | (1/4) 25% | (1/4) 25% | |||
| P-value* | 0.12 | 0.31 | 1 |
*Chi-square test with p value < 0.05 is considered significant.
a Warfarin Sensitive group (required minimum warfarin dose < 21 mg/week).
b Warfarin Moderate response group (required average warfarin dose between 21 and 49 mg/week).
c Warfarin Resistance group (required high warfarin dose > 49 mg/week).